&nbsp;

Dec 2024

Drug

cetuximab

Other Name(s): Erbitux®

Quick Link(s):

Aug 2023

Drug

temsirolimus

Other Name(s): Torisel ®

Quick Link(s):

Jun 2024

Drug

cabazitaxel

Other Name(s): Jevtana®

Quick Link(s):

Nov 2024

Drug

carfilzomib

Other Name(s): Kyprolis®

Quick Link(s):

Feb 2024

Regimen

TEMS

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

New Drug Funding Program

Temsirolimus - Metastatic Renal Cell Carcinoma

Drugs Used:

temsirolimus

... Show more tags

Quick Link(s):

Regimen Monograph

Jun 2024

Regimen

CYCLDOCE; CYCLDOCE+TRAS

Cancer Type:

Breast

Intent: Adjuvant

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph, Patient Info Sheet (CYCLDOCE)

Jan 2024

Regimen

CAPECISP+TRAS

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer

ODB - General Benefit

capecitabine

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

CISPFU+TRAS

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

CRBPDOCETRAS

Cancer Type:

Breast

Intent: Neoadjuvant, Adjuvant

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Feb 2022

Regimen

CISPRALT

Cancer Type:

Lung,

Mesothelioma (Pleural)

Intent: Palliative

Funding:

New Drug Funding Program

Raltitrexed - Advanced Malignant Pleural Mesothelioma (MPM)

Drugs Used:

raltitrexed,

CISplatin

... Show more tags

Quick Link(s):

Regimen Monograph

Oct 2024

Regimen

CVP+R

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

ODB - General Benefit

prednisone

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

Drugs Used: